Chest acne is not
the same as facial acne.

Truncal acne — encompassing the chest, back, and shoulders — is far more common than most people assume, and the chest is among the most frequently affected sites. The 2011 survey by Dréno et al. in the Journal of the European Academy of Dermatology and Venereology included over 6,700 acne patients across Europe and found that 52% had truncal acne alongside facial involvement. Of those with truncal acne, the chest was affected in roughly 30% of cases, second only to the back.

Despite its prevalence, truncal acne receives disproportionately little attention in clinical research and dermatological practice. Several review authors have noted that most acne clinical trials measure outcomes exclusively on the face, leaving truncal acne undertreated and poorly characterized. Patients frequently report that their dermatologist focused on their face while their chest and back breakouts went unaddressed, even when those were the more bothersome sites.

Truncal acne severity does not always mirror facial acne severity. Some people have mild facial acne but moderate-to-severe chest or back acne; others have clear faces and persistent chest breakouts. The two presentations share underlying pathophysiology — excess sebum, follicular hyperkeratinization, Cutibacterium acnes overgrowth, and inflammation — but the specific drivers and proportional contribution of each factor differ between the face and trunk. Treating chest acne effectively requires recognizing it as its own clinical entity, not simply an extension of facial acne.

Demographic factors also shape chest acne patterns. It is somewhat more common in males, likely due to higher androgen levels driving greater sebaceous gland activity on the trunk. However, women frequently develop chest breakouts in association with hormonal fluctuations — particularly premenstrually and during periods of elevated androgen activity. Athletes, particularly those in contact sports or who train in tight synthetic fabrics, represent a high-risk group regardless of sex.

The chest is one of the most sebaceous regions of the human body. Sebaceous gland density on the chest rivals that of the face — particularly the forehead and nose — and far exceeds that of regions like the arms and legs. A higher density of sebaceous glands means more sebum production per unit of skin area, creating the substrate for comedone formation. When sebum production is further amplified by androgens, the chest becomes especially vulnerable to breakouts.

Follicle anatomy on the chest also contributes to acne risk. The pilosebaceous units on the trunk tend to have wider follicular openings than on the face, which might seem protective against comedone formation. However, the same openings that allow sebum to exit more freely also serve as entry points for environmental debris, sweat residue, and occlusive fabrics — and the follicles are still subject to hyperkeratinization when androgen signaling is high. The result is that chest acne often presents as a mix of large comedones and inflammatory lesions.

The skin barrier on the chest differs from facial skin in ways that affect acne dynamics. Chest skin is generally thicker and less seborrheic than the T-zone of the face, but it is also more frequently compromised by friction from clothing. Transepidermal water loss patterns differ, and the chest is less frequently exfoliated or treated with the regularity applied to the face. This creates a situation where dead cells accumulate in follicles more readily, contributing to comedone formation even in the absence of excess sebum.

Hormone receptor distribution matters here too. Androgen receptors are expressed in sebaceous glands across the body, but their density and sensitivity vary by site. Research has shown that truncal sebaceous glands respond to androgen stimulation in a pattern that parallels — but is not identical to — facial glands. This is why some hormonal treatments, particularly combined oral contraceptives, produce clear-face responses that do not fully extend to the chest and back.

Unlike the face, which is almost always uncovered, the chest is routinely subjected to occlusion — the prolonged contact of skin with fabric that traps heat, moisture, and sebum against the follicular openings. Occlusion is a well-established acne trigger; it creates a local environment that promotes follicular hyperkeratinization, slows the natural shedding of dead skin cells, and allows C. acnes to proliferate in the anaerobic, lipid-rich conditions it prefers.

Tight clothing is a particularly significant driver of chest breakouts. Sports bras, compression tops, and athletic wear that fit snugly against the chest create sustained pressure and friction across the sternal and subclavicular areas. Friction from fabric edges — bra straps, necklines, the lower band of sports bras — creates a distinctive pattern of breakouts that follows the garment's outline rather than the natural sebaceous distribution. Dermatologists classify this as acne mechanica, a subtype driven by mechanical pressure and friction rather than solely by endogenous hormonal or microbial factors.

Sweat compounds the problem significantly. Sweat itself does not directly cause acne — it is mostly water and electrolytes — but it creates conditions that promote acne formation when it is trapped against the skin. Occlusive fabric prevents evaporative cooling, keeping sweat pooled in the follicular environment. This raises local humidity, softens the follicular wall, and creates a more favorable environment for C. acnes proliferation. Post-exercise skin that is not promptly cleansed retains sweat residue along with topically applied sunscreen, moisturizer, or other products that can further occlude pores.

The timing of chest breakouts relative to physical activity is one of the clearest clinical signals for identifying occlusion and sweat as drivers. If breakouts cluster in the areas covered by your sports bra or tight shirt, appear predominantly after days of intense exercise, and are worsened by wearing synthetic fabrics compared to cotton, the mechanica and sweat contribution is likely dominant. This pattern can coexist with hormonal or dietary drivers — most chest acne cases are multifactorial — but identifying and addressing the mechanical component is often the fastest route to improvement.

One of the most important distinctions in chest dermatology is between conventional acne and Malassezia folliculitis — a condition that looks almost identical to acne but has an entirely different cause and requires completely different treatment. Malassezia folliculitis (also called pityrosporum folliculitis) is caused by an overgrowth of Malassezia, a genus of lipophilic yeast that lives on human skin as a normal commensal organism.

Malassezia folliculitis presents as clusters of small, uniform, itchy papules and pustules — predominantly on the chest, upper back, and shoulders. Unlike conventional acne, there are typically no comedones (blackheads or whiteheads), and the lesions tend to be more similar in size and appearance than acne lesions. The itch is a key distinguishing feature; conventional acne lesions do not itch, while Malassezia folliculitis often produces noticeable pruritus, particularly after sweating or in hot, humid conditions.

The chest is a preferred site for Malassezia folliculitis for several reasons. Malassezia requires lipids to survive, and the sebum-rich environment of the chest provides ample nutrition. The yeast proliferates when the normal microbiome balance is disrupted — commonly by prolonged use of broad-spectrum oral antibiotics (which eliminate bacterial competitors), by heat and humidity that favor yeast overgrowth, or by occlusive clothing that creates the warm, moist conditions the yeast prefers. Immunosuppressed individuals and those who have used topical or systemic corticosteroids are also at elevated risk.

The treatment implications are significant. Conventional acne treatments — topical retinoids, benzoyl peroxide, and antibiotics — do not effectively treat Malassezia folliculitis and may worsen it if antibiotics further disrupt the microbiome. Malassezia folliculitis responds to antifungal treatment: topical ketoconazole shampoo (used as a body wash), selenium sulfide, or oral antifungals in more severe cases. If your chest breakouts do not respond to standard acne treatments, have an itchy quality, and appear as uniform small papules rather than a mixed lesion profile, Malassezia folliculitis should be considered. A dermatologist can confirm the diagnosis with a KOH preparation or Wood's lamp examination.

The hormonal drivers of chest acne are the same as those behind facial acne — primarily androgens acting on sebaceous glands — but the clinical expression differs. Androgens, particularly testosterone and its more potent metabolite dihydrotestosterone (DHT), stimulate sebaceous gland proliferation and sebum production throughout the body. The chest, with its high density of androgen-responsive sebaceous glands, is one of the more sensitive truncal regions.

In women, chest acne frequently follows a cyclical pattern tied to the menstrual cycle. Sebum production peaks in the week before menstruation, when progesterone levels are high and estrogen is declining. This hormonal window promotes follicular hyperkeratinization and creates conditions favorable for inflammatory lesion development. Women who notice that their chest breakouts worsen premenstrually and improve in the follicular phase of their cycle (days 1–14) are experiencing a classic hormonally-driven pattern. This pattern often coexists with jaw and chin acne, another hormonally sensitive distribution.

Conditions that raise androgen levels — polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, androgen-secreting tumors (rare), and anabolic steroid use — can produce severe and persistent truncal acne including significant chest involvement. In clinical practice, a sudden onset of severe chest acne in a woman, especially accompanied by other signs of androgen excess (hirsutism, irregular periods, scalp hair thinning), warrants laboratory investigation. Anabolic steroid use in athletes is a particularly common driver of truncal acne and should always be considered in fitness-oriented individuals.

Hormonal contraceptives affect chest acne differently depending on formulation. Combined oral contraceptives (COCs) that have anti-androgenic progestins — such as drospirenone, cyproterone acetate, or norgestimate — can meaningfully reduce androgen-driven chest acne. However, progestin-only methods, including some hormonal IUDs and implants, may worsen acne in women with androgenic sensitivity by activating androgen receptors. Tracking chest acne patterns relative to hormonal contraceptive changes gives clinically useful data for guiding treatment decisions.

One of the most important reasons to take chest acne seriously — beyond cosmetic concern — is the substantially elevated risk of problematic scarring on the trunk compared to the face. The chest and upper back are predisposed to keloid and hypertrophic scar formation in a way that facial skin is not, and inflammatory acne lesions in these regions can leave permanent, raised, fibrous scars that are far more difficult to treat than the post-inflammatory hyperpigmentation common on the face.

Keloids are abnormal scars that grow beyond the original wound boundary, driven by an exaggerated fibroblast response and excess collagen deposition. The sternal (breastbone) region of the chest has the highest keloid predisposition of virtually any body site. Research has consistently shown that the sternal and deltoid regions are among the most common locations for spontaneous keloid formation, and any disruption to the skin — including acne lesions — can trigger their development in susceptible individuals. Hypertrophic scars are similar but remain within the wound boundary; both types are more common on the chest than on the face.

Genetic predisposition plays a significant role in scar type. People of African, Hispanic, and Asian descent have higher rates of keloid formation than individuals of European descent, making chest acne particularly consequential for these populations. A personal or family history of keloid or hypertrophic scarring should prompt proactive rather than reactive acne management — waiting until lesions are severe before seeking treatment greatly increases the window for scar formation.

The clinical implication is straightforward: chest acne should be treated more aggressively and earlier than its severity might otherwise suggest, specifically because the cost of inadequate treatment — permanent raised scarring on a visible area — is higher than on the face. Squeezing or picking chest lesions carries an especially high cost in terms of scar risk and should be avoided entirely. Systematic tracking of chest breakout patterns can help identify triggers early — enabling intervention before lesions become deep, inflammatory, and scar-prone.